Oncology Drug Spending By Health Plans May Rise 50% By 2010 – Medco
Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")
You may also be interested in...
Prescription Drug Spending Remains Low, As Generics Continue To Dominate -Medco
OTC entries drive Rx utilization down.
WellCare Government Membership Up But Costs May Lead To Loss
WellCare anticipates a net loss in the first quarter 2008, versus net income of $25 million in the first quarter of 2007, due to higher medical expenses and costs associated with ongoing government and special committee investigations
GSK’s Promacta slated for committee review
GlaxoSmithKline's idiopathic thrombocytopenic purpura therapy Promacta will undergo a review by FDA's Oncologic Drugs Advisory Committee May 30. GSK is seeking approval for short-term, second-line use of Promacta (eltrombopag) to increase platelet counts and reduce or prevent bleeding in patients with chronic ITP. The company plans to follow up with a broader application for chronic ITP this year. Amgen's platelet producer Nplate (romiplostim) recently received ODAC support, but a major amendment has since delayed the application (1"The Pink Sheet," March 17, 2008, p. 3)...